From the analyst's couch: Drug discovery alliances

Nature Reviews Drug Discovery

Volumn 4, Issue 10, 2005, Pages 807-808

  Jones, Andrew ^a   Clifford, Les ^a  

^a Ernst and Young Global Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; GEMTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY;

BIOTECHNOLOGY; CANCER RESEARCH; COMPETENCE; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG PROGRAM; DRUG RESEARCH; ECONOMIC EVALUATION; FINANCIAL MANAGEMENT; HEALTH CARE FACILITY; INVESTMENT; LICENSING; NOTE; ORGANIZATION; PRIORITY JOURNAL; RISK MANAGEMENT; ARTICLE; CHEMISTRY; DRUG DESIGN; ECONOMICS; INTERNATIONAL COOPERATION; MEDICAL RESEARCH; METHODOLOGY; PHARMACEUTICS; PUBLIC RELATIONS; STATISTICS;

BIOMEDICAL RESEARCH; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG INDUSTRY; INTERINSTITUTIONAL RELATIONS; INTERNATIONAL COOPERATION; TECHNOLOGY, PHARMACEUTICAL;

EID: 27644527041     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1856     Document Type: Note

References (2)

1. Booth, B. From the analyst's couch: With cash multiples. Nature Rev. Drug Discov. 4, 533-534 (2005).
2. Beyond Borders: Ernst & Young Global Biotechnology Report (Ernst & Young, London, 2005).